News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,322 Results
Type
Article (668)
Company Profile (1)
Press Release (12652)
Section
Business (3536)
Career Advice (2)
Deals (856)
Drug Development (1291)
Employer Resources (1)
FDA (259)
Job Trends (136)
News (5971)
Policy (545)
Tag
Academia (22)
Alliances (1645)
ALS (1)
Alzheimer's disease (8)
Antibody-drug conjugate (ADC) (1)
Approvals (260)
Artificial intelligence (4)
Autoimmune disease (1)
Bankruptcy (1)
Best Places to Work (105)
Biosimilars (5)
Bladder cancer (2)
Breast cancer (9)
Cancer (47)
Cardiovascular disease (2)
Career advice (2)
CDC (1)
Cell therapy (6)
Clinical research (1088)
Collaboration (33)
Compensation (9)
COVID-19 (101)
CRISPR (1)
C-suite (12)
Cystic fibrosis (1)
Data (60)
Diabetes (3)
Diagnostics (135)
Drug discovery (2)
Drug shortages (1)
Earnings (904)
Employer resources (1)
Events (1155)
Executive appointments (6)
FDA (289)
Funding (15)
Gene editing (2)
Gene therapy (7)
GLP-1 (13)
Government (47)
Guidances (5)
Healthcare (322)
IgA nephropathy (1)
Immunology and inflammation (2)
Infectious disease (101)
Intellectual property (4)
Interviews (1)
IPO (227)
Job creations (32)
Job search strategy (2)
Layoffs (5)
Legal (159)
Liver cancer (1)
Lung cancer (5)
Lymphoma (1)
Management (1)
Manufacturing (14)
Medical device (185)
Medtech (186)
Mergers & acquisitions (645)
Metabolic disorders (5)
Multiple sclerosis (4)
Neuropsychiatric disorders (1)
Neuroscience (16)
NextGen: Class of 2025 (46)
Non-profit (4)
Obesity (2)
Opinion (2)
Pain (6)
Pancreatic cancer (1)
Patents (3)
Patient recruitment (5)
People (838)
Pharmaceutical (1)
Phase I (362)
Phase II (482)
Phase III (399)
Pipeline (33)
Policy (1)
Postmarket research (41)
Preclinical (127)
Prostate cancer (2)
Radiopharmaceuticals (6)
Rare diseases (6)
Real estate (127)
Regulatory (393)
Reports (1)
Research institute (29)
Series A (5)
Service/supplier (1)
Startups (86)
Supply chain (1)
The Weekly (1)
Vaccines (24)
Date
Today (2)
Last 7 days (11)
Last 30 days (54)
Last 365 days (354)
2025 (316)
2024 (456)
2023 (558)
2022 (1873)
2021 (1729)
2020 (1214)
2019 (758)
2018 (487)
2017 (662)
2016 (529)
2015 (749)
2014 (579)
2013 (492)
2012 (564)
2011 (503)
2010 (429)
Location
Africa (7)
Arizona (1)
Asia (612)
Australia (175)
California (50)
Canada (35)
China (3)
Delaware (5)
Europe (5465)
Florida (7)
Georgia (1)
Idaho (1)
Illinois (12)
Indiana (1)
Japan (13)
Maryland (6)
Massachusetts (61)
Michigan (9)
New Jersey (22)
New York (8)
North Carolina (9)
Northern California (36)
Pennsylvania (69)
South America (17)
Southern California (6)
Texas (4)
United States (272)
Utah (7)
Washington State (1)
Wisconsin (1)
13,322 Results for "curevac gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
BioNTech Swallows Vaccine Rival CureVac in $1.25B All-Stock Acquisition
BioNTech will get CureVac’s early-stage cancer assets, including its mRNA-based glioblastoma therapy currently in Phase I development. CureVac had previously sued BioNTech for copyright infringement related to mRNA vaccine technology.
June 12, 2025
·
3 min read
·
Tristan Manalac
Press Releases
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
October 22, 2025
·
18 min read
Press Releases
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
August 18, 2025
·
11 min read
Legal
BioNTech Attacked CureVac’s ‘Failed’ COVID Vaccine Program. The Rivals Are Now Merging
BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Now, the mRNA biotech is buying that very company.
June 18, 2025
·
4 min read
·
Nick Paul Taylor
Press Releases
BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer
June 12, 2025
·
17 min read
Press Releases
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
May 20, 2025
·
10 min read
Press Releases
IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH
November 3, 2025
·
2 min read
Press Releases
Croma-Pharma GmbH Enters Strategic Distribution Partnership with Renellence in Canada
October 10, 2025
·
2 min read
Press Releases
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
May 15, 2025
·
6 min read
Press Releases
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
April 8, 2025
·
4 min read
1 of 1,333
Next
